ZA201405610B - Prediction of outcome in patients with chronic obstructive pulmonary disease - Google Patents

Prediction of outcome in patients with chronic obstructive pulmonary disease

Info

Publication number
ZA201405610B
ZA201405610B ZA2014/05610A ZA201405610A ZA201405610B ZA 201405610 B ZA201405610 B ZA 201405610B ZA 2014/05610 A ZA2014/05610 A ZA 2014/05610A ZA 201405610 A ZA201405610 A ZA 201405610A ZA 201405610 B ZA201405610 B ZA 201405610B
Authority
ZA
South Africa
Prior art keywords
outcome
prediction
patients
pulmonary disease
chronic obstructive
Prior art date
Application number
ZA2014/05610A
Other languages
English (en)
Inventor
Michael Tamm
Daiana Stolz
Sven Giersdorf
Original Assignee
Brahms Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47780019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201405610(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brahms Gmbh filed Critical Brahms Gmbh
Publication of ZA201405610B publication Critical patent/ZA201405610B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA2014/05610A 2012-03-08 2014-07-29 Prediction of outcome in patients with chronic obstructive pulmonary disease ZA201405610B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12001590.4A EP2637023A1 (en) 2012-03-08 2012-03-08 Prediction of outcome in patients with chronic obstructive pulmonary disease
PCT/EP2013/000558 WO2013131621A1 (en) 2012-03-08 2013-02-26 Prediction of outcome in patients with chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
ZA201405610B true ZA201405610B (en) 2015-12-23

Family

ID=47780019

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/05610A ZA201405610B (en) 2012-03-08 2014-07-29 Prediction of outcome in patients with chronic obstructive pulmonary disease

Country Status (11)

Country Link
US (1) US20150080246A1 (enExample)
EP (3) EP2637023A1 (enExample)
JP (1) JP6117251B2 (enExample)
CN (1) CN104126125B (enExample)
BR (1) BR112014019349A8 (enExample)
DK (1) DK2823314T3 (enExample)
ES (1) ES2631653T3 (enExample)
IN (1) IN2014DN07813A (enExample)
RU (1) RU2688168C2 (enExample)
WO (1) WO2013131621A1 (enExample)
ZA (1) ZA201405610B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013217935B2 (en) 2012-02-09 2018-05-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
EP2637023A1 (en) 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
RU2730836C2 (ru) 2014-08-14 2020-08-26 Мемед Диагностикс Лтд. Вычислительный анализ биологических данных с применением многообразия и гиперплоскости
WO2016075054A1 (en) * 2014-11-12 2016-05-19 Koninklijke Philips N.V. Apparatus and method for assessing the severity of chronic obstructive pulmonary disease, copd, in a subject
EP3230740B1 (en) 2014-12-11 2025-05-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
CA2986097A1 (en) * 2015-05-18 2016-11-24 The University Of British Columbia Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd
CA3015046A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
CN107229813A (zh) * 2016-03-24 2017-10-03 深圳中迈数字医疗技术有限公司 实施监护的判断方法及系统
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) * 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
CA3052349C (en) * 2017-02-02 2024-06-04 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event
WO2018191560A1 (en) * 2017-04-12 2018-10-18 Proterixbio, Inc. Biomarker combinations for monitoring chronic obstructive pulmonary disease and/or associated mechanisms
CN107267658B (zh) * 2017-08-21 2018-11-02 常州市第二人民医院 Copd诊断用分子标志物
JP7291688B2 (ja) * 2017-09-13 2023-06-15 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 重篤患者における腎置換療法のための指標としてのアドレノメズリン前駆体
EP4027145A1 (en) * 2017-09-13 2022-07-13 B.R.A.H.M.S GmbH Pro-adm for therapy monitoring of intensive care unit patients
JP7366007B2 (ja) * 2017-09-13 2023-10-20 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
CN108424969B (zh) * 2018-06-06 2022-07-15 深圳市颐康生物科技有限公司 一种生物标志物、诊断或预估死亡风险的方法
CN109218131B (zh) * 2018-09-03 2022-03-29 平安医疗健康管理股份有限公司 网络监控方法、装置、计算机设备和存储介质
US20220196678A1 (en) * 2019-02-21 2022-06-23 B.R.A.H.M.S. Gmbh Method for the diagnosis of macce in patients who underwent gastrointestinal surgery
FR3094491B1 (fr) * 2019-03-28 2024-07-19 Rheonova Méthode in vitro de diagnostic, de stratification, de pronostic et/ou de suivi d'une maladie des poumons et/ou une maladie respiratoire
CN110850006B (zh) * 2019-12-20 2020-11-20 河南中医药大学 一种慢性阻塞性肺病诊断试剂及试剂盒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
SI2019965T1 (sl) * 2006-05-02 2015-10-30 Critical Care Diagnostics, Inc. Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
PT3093663T (pt) * 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
US20100159474A1 (en) * 2008-11-11 2010-06-24 B.R.A.H.M.S. Aktiengesellschaft Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
GB0911007D0 (en) * 2009-06-25 2009-08-12 Univ Hospital Of North Staffordshire Analyzer apparatus and methods for lung disease
CN102253220B (zh) * 2011-06-07 2014-04-09 复旦大学附属中山医院 用于诊断慢性阻塞性肺病急性加重期的试剂盒
EP2637023A1 (en) 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease

Also Published As

Publication number Publication date
DK2823314T3 (en) 2017-07-03
ES2631653T3 (es) 2017-09-01
BR112014019349A2 (enExample) 2017-06-20
EP2823314A1 (en) 2015-01-14
WO2013131621A8 (en) 2014-06-12
CN104126125B (zh) 2017-03-01
EP2823314B1 (en) 2017-04-12
EP2637023A1 (en) 2013-09-11
BR112014019349A8 (pt) 2017-07-11
IN2014DN07813A (enExample) 2015-07-10
EP3232201A1 (en) 2017-10-18
HK1198556A1 (en) 2015-05-15
CN104126125A (zh) 2014-10-29
RU2014140608A (ru) 2016-04-27
US20150080246A1 (en) 2015-03-19
RU2688168C2 (ru) 2019-05-20
WO2013131621A1 (en) 2013-09-12
JP2015509596A (ja) 2015-03-30
JP6117251B2 (ja) 2017-04-19

Similar Documents

Publication Publication Date Title
IL239025A0 (en) Treatment of lung disease
EP2913047A4 (en) Pulmonary disease-specific therapeutic agent
PT2939022T (pt) Biomarcadores de nascimento prematuro
KR102297388B9 (ko) 대사장애를 치료하기 위한 아커만시아의 용도
LT3354747T (lt) Neinvazinis naviko metilomos nustatymas iš plazmos
EP2710370A4 (en) METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
SG11201500272XA (en) Authorization of transactions
ZA201405871B (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
EP2840938A4 (en) THERAPEUTIC CUSHION
PT2739750T (pt) Doença cardiovascular
SG11201601807XA (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
IL230738A0 (en) Co-crystals of cyprodinil and dithianone
EP2823818A4 (en) USE OF RUPATADINE IN THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBSTRUCTIVE CHRONIC BRONCHOPNEUMOPATHY
HUE059569T2 (hu) Aklidinium alkalmazása krónikus obstruktív tüdõbetegségben szenvedõ beteg napi fizikai tevékenységének növelésében
GB201217330D0 (en) Therapeutic for treating inflammatory lung disorders
IL236496A0 (en) A medicine against gastroesophageal reflux disease
IL233568A0 (en) A method for treating obstructive lung disease
HUE039105T2 (hu) Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
LT2702033T (lt) 3-karboksi-n-etil-n,n-dimetilpropan-1-amino druskos panaudojimas kardiovaskuliarinių ligų gydyme
GB201101770D0 (en) Treatment of inflammatory respiratory disease
GB201201778D0 (en) Treatment of inflammatory respiratory disease
GB201118269D0 (en) Treatment of cardiovascular disease
GB201107988D0 (en) Treatment of cardiovascular disease
GB201219092D0 (en) Treatment of cardiovascular disease
GB201204645D0 (en) Treatment of disease